SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1

SARS-CoV-2 is the etiological agent of COVID19. There are currently several licensed vaccines approved for human use and most of them target the spike protein in the virion envelope to induce protective immunity. Recently, variants that spread more quickly have emerged. There is evidence that some o...

Descripción completa

Detalles Bibliográficos
Autores principales: Law, John Lok Man, Logan, Michael, Joyce, Michael A., Landi, Abdolamir, Hockman, Darren, Crawford, Kevin, Johnson, Janelle, LaChance, Gerald, Saffran, Holly A., Shields, Justin, Hobart, Eve, Brassard, Raelynn, Arutyunova, Elena, Pabbaraju, Kanti, Croxen, Matthew, Tipples, Graham, Lemieux, M. Joanne, Tyrrell, D. Lorne, Houghton, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387217/
https://www.ncbi.nlm.nih.gov/pubmed/34481699
http://dx.doi.org/10.1016/j.vaccine.2021.08.081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387217/
https://www.ncbi.nlm.nih.gov/pubmed/34481699
http://dx.doi.org/10.1016/j.vaccine.2021.08.081

Ejemplares similares